NNVC vs NRXS

NanoViricides, Inc. vs Neuraxis, Inc. — Valuation Comparison 2026

NNVC

Biotechnology
NanoViricides, Inc.
Quality
4.3
out of 10
Value Trap
30
LOW
Price
$1.86
Last close
Models
7/13
Active
VS

NRXS

Biotechnology
Neuraxis, Inc.
Quality
6.9
out of 10
Value Trap
18
SAFE
Price
$7.29
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType NNVC Fair ValueNNVC Upside NRXS Fair ValueNRXS Upside
Bayesian DCF Intrinsic $0.57 -69.1% $2.04 -72.0%
Earnings Power Value Intrinsic $1.57 -80.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.00 -46.4% $0.86 -88.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NNVC vs NRXS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NNVC vs NRXS — Which Stock Is More Undervalued?

NRXS scores higher with a 6.9/10 quality rating vs NNVC's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NanoViricides, Inc. (NNVC) and Neuraxis, Inc. (NRXS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NNVC currently trades at $1.86 with a QOC of 4.3/10, while NRXS trades at $7.29 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).